

## CURRICULUM VITAE



### CONTACT:

**Name:** Prof dr Lazar Popović, MD, PhD

**Licence number:** 203866

**Date of birth:** 23.07.1979. in Novi Sad, Serbia

### Address:

**Home:** Nova III 14 , Petrovaradin

**Job:** Head of Department for Onco-Hematology, Clinic for medical oncology, Oncology Institute of Vojvodina, Put dr Goldmana 4, 21204 Sremska Kamenica, Serbia

Associate Professor, Faculty of Medicine, University of Novi Sad

ESMO Practicing Oncologists Working Group Member

### Phone numbers:

**Mobile:** +381638041910

**Job:** +381214805418

**e-mail:** [lazar.popovic@yahoo.com](mailto:lazar.popovic@yahoo.com)

### EDUCATION:

**1994-1998 Gymnasium** “Jovan Jovanović Zmaj”, in Novi Sad, science and mathematics,

**1998-2004 Medical faculty**, in Novi Sad, **Medicine doctor** average 9,39/10.

**2008-2011 Specialisation: Internal medicine**

**2013-2015 Subspecialisation: Oncology**

**2014 PhD** “Significance of molecular markers expression in prognosis of diffuse large B-cell lymphoma treated with immunochemotherapy”

**WORKING EXPERIENCE:**

**2004-2005 One year intership:** Clinic for nephrology and clinical immunology, Clinical Centre of Vojvodina.

**2005-2011 Medical doctor:** Clinic for medical oncology, Oncology Institute of Vojvodina

**2011-2015 Medical doctor, Internal medicine consultant:** Clinic for medical oncology, Oncology Institute of Vojvodina

**2015- Medical doctor, Internal medicine consultant, oncology subspecialist:** Clinic for medical oncology, Oncology Institute of Vojvodina

**2006-2014 Teaching assistant:** Department of oncology, Medical faculty, Univeristy of Novi Sad

**2014-2019 Assistant Professor:** Department of oncology, Medical faculty, Univeristy of Novi Sad

**2019- 2024 Associate Professor:** Department of oncology, Medical faculty, Univeristy of Novi Sad

**2024- Full Professor:** Department of oncology, Medical faculty, Univeristy of Novi Sad

**2019- Head of Department for Onco-hematology**

**2021-2024 ESMO Practicing Oncologists Working Group Member**

**2021-2024 ESMO OncologyPRO associated editorial Board Member**

**2024- ESMO Virtual Journal Club (VJC) Selection Panel Member**

**FOREIGN LANGUAGES:**

**English**-fluently

**German**-beginner course (DAAD)

**EDUCATION and EXPERIENCE:**

**2008 Professional education:** Tenon Hospital, Paris, Medical Oncology and stem cell transplantation unit (Prof Lotz/ Prof Gligorov)

**2016 ESMO Clinical Unit Visit Fellowship Grant:** Oncology Institute Southern Switzerland, Lymphoma Unit, Breast Cancer Unit, Phase 1 Trials Unit (Prof Cavalli/Prof Ghielmini/Dr Zucca/Dr Pagani/Dr Stathis)

**2006 Course "Apheresis on Cobe spectra"**

**2007 GCP course** certificate

**2012 GCP recerification** Quintiles

**2008 EBMT-Lymphoma** working party training course

**2009 EBMT-Infectious diseases** working party training course

**2011 EBMT-Medical statistics** course

**2012 Top 10 Teaching assistants at Medical Faculty of Novi Sad-Award of Students**

**2017 Health Management Academy "Franklin Covey" course**

**2020 "Olaf & McAteer" Communication with Media Course**

## **MEMBERSHIPS:**

**BUON (Balkans Union of Oncology) member**

**ESMO (European Society for Medical Oncology) member**

**ESMO YO-National Representative (2015-2019)**

**SLG (Serbian Lymphoma Study Group) member**

**SLD (Serbian Medical Society) member**

**AROME JUNIOR executive board member-research co-ordinator**

**AJOC (AROME Junior Oncologist Committee)-hematological malignancies co-coordinator (2012-2016)**

**AROME (Association of Radiotherapy and Oncology in the Mediterranean Area) national board member**

**NOVI SAD ONCOLOGY CONGRESS 2009., 2010. and 2012. Head of Congress Secretariat**

**NOVI SAD ONCOLOGY CONGRESS 2014., 2015, 2016, 2017, 2018, 2019 Organizing committee member**

**NOVI SAD ONCOLOGY CONGRESS 2020 Head of Organizing Committee**

**ARCHIVE OF ONCOLOGY journal editor 2013-2015, 2017-**

**ARCHIVE OF ONCOLOGY journal Editor-in-Chief 2015-2017**

**ONCOLOGY INSTITUTE OF VOJVODINA DRG IMPLEMENTATION TEAM 2013-2015**

**ONCOLOGY INSTITUTE OF VOJVODINA ACREDITATION TEAM (Medical oncology dept and Information technologies teams) 2014-2015**

**FRONTIERS IN ONCOLOGY Associate Editor (2020-) Breast cancer section**

## **PROJECTS**

“Maintaining Quality of Oncology Service in Autonomous Province of Vojvodina”-Educational Project, Ministry of Health, Autonomous Province of Vojvodina 2015-2016

„Improving the knowledge of health workers about the modalities of treatment of urooncological diseases“ Educational Project, Ministry of Science, Autonomous Province of Vojvodina, 2022, Project Leader

## **CLINICAL TRIALS:**

### **GLOBAL PRINCIPAL INVESTIGATOR**

MO42921 VANESSA Trial: A Multicenter Observational Study to Evaluate the Prevalence of PD-L1 and its Role in Patients with TNBC Treated with Systemic Therapy

## **INSTITUTIONAL PRINCIPAL INVESTIGATOR:**

**PHASE III:** Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

**PHASE II/III:** A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

**PHASE III:** CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

**PHASE III:** A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

**PHASE III:** A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Adjuvant Endocrine-Based Therapy Without Disease Recurrence

**PHASE II:** A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF THE INTRAVENOUS FIXED-DOSE COMBINATION (IV FDC) OF TIRAGOLUMAB AND ATEZOLIZUMAB IN PARTICIPANTS WITH LOCALLY ADVANCED, RECURRENT OR METASTATIC SOLID TUMORS

**PHASE I:** A PHASE 1B, OPEN-LABEL, MULTICENTER, DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SOF10 IN COMBINATION WITH CHECKPOINT INHIBITORS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

**PHASE III INCMOR 0208-305:** A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

**PHASE III On Target:** A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Crofelemer For The Prophylaxis Of Diarrhea In Adult Patients With Solid Tumors Receiving Targeted-Cancer Therapies With Or Without Standard Chemotherapy Regimens

**PHASE II** A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac, Alone or in Combination with Pembrolizumab, with and without Intermittent Low-Dose Cyclophosphamide, in Subjects with Relapsed/Refractory Diffuse Large BCell Lymphoma

**PHASE III** A Phase III, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor–positive, HER2-negative Early Breast Cancer

**PHASE III:** A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

**PHASE III:** A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - The COASTAL Study.

**PHASE III:** A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)

**PHASE III** An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

**PHASE III** Protocol EV 302: An open- label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer

**PHASE II** KCP-330-009 A Phase 2B Open-Label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

**PHASE III** IPATUNITY170 A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.

**PHASE II** MARIO 275 A Phase 2 Multicenter, Randomized, Double Blind, Active Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination with IPI 549 Compared to Nivolumab Monotherapy in the Treatment of Patients with Immune Therapy Naïve, Advanced Urothelial Carcinoma

**PHASE II** Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy

**PHASE III** A Phase 3, Multicenter, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy

**PHASE Ib:** A Multi-Center, Single-Arm, Open-Label Phase 1b Study of a Novel FGFR3 Inhibitor (B-701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Following Platinum-based Chemotherapy

**PHASE III:** The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy (Imvigor130)

**PHASE I:** TO-TAS-102-107 A Phase 1, Open-Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Renal Impairment

**PHASE III:** A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma

**PHASE III:** A Phase III, Open-Label, Multicenter, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody, Atezolizumab) Compared With Chemotherapy In Patients With Locally Advanced Or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy

**PHASE III:** A phase 3, multicenter, randomized, double-blind, active control study to evaluate the safety and efficacy of IV pro-netupitant/palonosetron (260 mg/0.25 mg) combination for the prevention of chemotherapy-induced nausea and vomiting in repeated chemotherapy cycles in patients receiving highly emetogenic chemotherapy

**PHASE IV:** DIREGL07274-Metastatic Castrate Resistant Prostate Cancer-Serbian Registry

#### **SUB-INVESTIGATOR:**

**PHASE I:** Her-2 positive breast cancer; Aggressive Lymphoma.

**PHASE II:** Multiple myeloma, Diffuse Large B-Cell Lymphoma, Low Grade Lymphoma

**PHASE III:** Bladder Cancer-Immunotherapy (anti-PD-L1 adjuvant) , Multiple myeloma, Breast cancer (4 trials); Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Cancer and Coagulation (2 trials), Glioblastoma, Melanoma.

**PHASE IV:** Diffuse Large B-cell Lymphoma (2 trials), Follicular Lymphoma (2 trials), CLL, Mantle Cell Lymphoma

#### **INTERESTS and KNOWLEDGE:**

Breast cancer

Urological cancers (prostate, bladder, renal, testis)

Lymphoma/CLL

Cancer Immunotherapy

Multiple myeloma

Biomarkers and signaling pathways in cancer

Target therapy

Autologous stem cell transplantation

Supportive care in cancer

Pharmacoeconomy and management

Clinical trials

#### **FREE TIME:**

Sport: basketball, soccer, swimming

Music: playing drums

#### **REFERENCES:**

#### **BOOKS:**

Matovina-Brko G, Popovic L Karcinom dojke I gojaznost u Stokic E. Gojaznost je bolest koja se leči (drugi deo) 2018 Medicinski fakultet Novi Sad ISBN 978-86-7197-549-0

Cvetanovic A, Popovic L, Zivkovic N, Matovina-Brko G, Filipovic S, Kostic M, Vrbic S, Pejcic I Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A New Key in the Hands of Oncologists in Watanabe HS Horizons in Cancer Research Vol 65 Nova Science Publishing 2017 ISBN: 978-1-53610-954-2

Milic-Torres V, Popovic L, Vaz F, Penque D Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications in Ruef J and Sebastiao Rodrigues Cancer Drug Resistance: Overview and Methods. Methods in Molecular Biology vol 1395 DOI 10.1007/978-1-4939-3347-1\_16 Springer Science and Business Media New York 2016

Cvetanovic A, Filipovic S, Vrbic S, Pejcic I, Popovic L Side effects of cetuximab: rash in Madison R Hall. Head and neck cancer: epidemiology, management and treatment outcomes Nova Science Publishers 2015 ISBN: 978-1-63482-113-1

Popovic L., Grgic Z., Popovic M. "Melanoma during pregnancy" in Armstrong A. Advances in Malignant Melanoma: Clinical and Research Perspectives InTech 2011 ISBN 978-953-307-575-4

Lucic S, Lučić M, Peter A, Erak M, Popovic-Petrovic S, Kukić B, Popović L, Đuran B. PET/CT in diagnosis of cancer of unknown primary, Aktualnosti u medicini i stomatologiji i farmaciji: Zbornik radova :Medicinski fakultet Novi Sad 2010 (serbian)

## **PAPERS:**

**Popović L**, Borštnar S, Božović-Spasojević I, Cvetanović A, Dedić Plavetić N, Kaneva R, Konsoulova A, Matos E, Tomić S, Vrdoljak E. Treatment Sequencing in Metastatic HR+/HER2- Breast Cancer: A Delphi Consensus. *Cancers (Basel)*. 2025 Apr 23;17(9):1412.

Rizzo M, Morelli F, Ürün Y, Buti S, Park SH, Bourlon MT, Grande E, Massari F, Landmesser J, Poprach A, Takeshita H, Roviello G, Myint ZW, **Popovic L**, Soares A, Abahssain H, Giannatempo P, Molina-Cerrillo J, Incorvaia L, Salah S, Zeppellini A, Monteiro FSM, Porta C, Gupta S, Santoni M. Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience. *Cancer Med*. 2025 Feb;14(4):e70479.

Incorvaia L, Scagliarini S, Marques Monteiro FS, Takeshita H, Tapia JC, Gandur Quiroga MN, Lam E, Tural D, **Popovic L**, Campos-Gomez S, Zucali PA, Mota A, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Abahssain H, Galosi AB, Badalamenti G, Kopecky J, Bamias A,

Landmesser J, Ansari J, Calabrò F, Massari F, Buti S, Bellmunt J, Santoni M. Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab. *Sci Rep.* 2025 Mar 14;15(1):8815.

E. Agostinetti, M. Bruzzone, A.-S. Hamy, H.J. Kim, C. Chiodi, R. Bernstein-Molho, S. Linn, K. Pogoda, E. Carrasco, F. Derouane, J. Bajpai, G. Nader-Marta, N. Lopetegui-Lia, A.H. Partridge<sup>13</sup>, L. Cortesi, C. Rousset-Jablonski, F. Giugliano, T. Renaud, A. Ferrari, S. Paluch-Shimon, R. Fruscio, W. Cui, S.M. Wong, C. Vernieri, K.J. Ruddy, M.V. Dieci, A. Matikas, M. Rozenblit, D. Aguilar y Mendez, L. De Marchis, R. Borea, F. Puglisi, M. Pistelli, J. Kufel-Grabowska, R. Di Rocco, E. Mariamidze, F. Atzori, H.R. Kourie, **L. Popovic**, E. de Azambuja, E. Blondeaux, M. Lambertini Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology *ESMO Open*, Volume 9, Issue 10, 103714

Cvetanovic A, Lambertini M, Punie K, Matovina-Brko G, Zivkovic N, Popovic M, Milovic-Kovacevic M, **Popovic L** Pharmacological methods for ovarian function and fertility preservation in women with cancer: A literature review Jun 2024 (Ahead of print) Doi: 10.32604/or.2024.049743

Sabale U, Karamousouli E, **Popovic L**, Krasznai ZT, Harrop D, Meiwald A, Hughes R, Weston G, Bencina G. The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs. *J Med Econ.* 2024 Apr;27(sup2):1-8. doi: 10.1080/13696998.2024.2341572. Epub 2024 Apr 30. PMID: 38638098.

Borstnar S, Bozovic-Spasojevic I, Cvetanovic A, Plavetic ND, Konsoulova A, Matos E, **Popovic L**, Popovska S, Tomic S, Vrdoljak E. Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies. *Radiol Oncol.* 2024 Jun 11;58(2):258-267. doi: 10.2478/raon-2024-0030. PMID: 38860691; PMCID: PMC11165977.

Popovic DS, Patoulias D, **Popovic LS**, Karakasis P, Papanas N, Mantzoros CS. Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract.* 2024 Jun 24;213:111758. doi: 10.1016/j.diabres.2024.111758. Epub ahead of print. PMID: 38925294.

Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, **Popovic L**, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Kùronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bissoni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, Rosellini M, Sorgentoni G, Battelli N,

Buti S, Porta C, Bellmunt J. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. *Cancer Immunol Immunother.* 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w. PMID: 38634928; PMCID: PMC11026312.

Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; **BRCA BCY Collaboration**. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. *JAMA.* 2024 Jan 2;331(1):49-59. doi: 10.1001/jama.2023.25463. PMID: 38059899; PMCID: PMC10704340.

Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Quiroga MNG, Gilbert D, **Popovic L**, Grande E, Mammone G, Berardi R, Crabb SJ, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Cattrini C, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchenhorn D, Santini D, Manneh R, Bissoni R, Zakopoulou R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Sorgentoni G, Battelli N, Porta C, Bellmunt J, Santoni M Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study *Cancer Immunol Immunother.* 2023 Sep 7. doi: 10.1007/s00262-023-03518-z. Online ahead of print.

Santoni M, Myint ZW, Büttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, Küronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, **Popovic L**, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabrò F, Porta C Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study *Cancer Immunol Immunother.* 2023 Sep;72(9):2961-2970.

**Popovic LS**, Matovina-Brko G, Popovic M, Punie K, Cvetanovic A, Lambertini M Targeting triple-negative breast cancer: A clinical perspective *Oncol Res.* 2023 May 24;31(3):221-238.

Goran Bencina, Nour Chami, Robert Hughes, Georgie Weston, Carl Baxter, Adam Maciejczyk, **Lazar Popovic**, Eugenia Karamousouli & Stina Salomonsson (2023) Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs, *Journal of Medical Economics*, 26:1, 254-261, DOI: 10.1080/13696998.2023.2169497

Pejčić T, Todorović Z, Đurašević S, **Popović L**. Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting. *International Journal of Molecular Sciences*. 2023; 24(3):2939. <https://doi.org/10.3390/ijms24032939>

Pejčić T, Zeković M, Bumbaširević U, Kalaba M, Vovk I, Bensa M, **Popović L**, Tešić Ž. The Role of Isoflavones in the Prevention of Breast Cancer and Prostate Cancer. *Antioxidants*. 2023; 12(2):368. <https://doi.org/10.3390/antiox12020368>

H. K. van Halteren<sup>1</sup> J. Bennouna, B. Brasiuniene, A. J. Cunquero Tomas, A. M. Garcia Trinidad, A. Indini, G. Liposits, B. Pellegrino, **L. Popovic**, A. Tan, R. Vidra and M. Strijbos Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data ESMO Open January 10, 2023  
DOI:<https://doi.org/10.1016/j.esmooop.2022.100773>

Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, **Popovic L**, Solinas C, Kok M, de Azambuja E, Lambertini M Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer *Expert Opin Investig Drugs*. 2022 Mar 9:1-25. doi: 10.1080/13543784.2022.2049232. Online ahead of print.

Popovic M, Matovina-Brko G, Jovic M, **Popovic LS**. Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma *World J Clin Oncol*. 2022 Jan 24;13(1):28-38.

Mauri D, Kamposioras K, Matthaios D, Tolia M, Nixon I, Dambrosio M, Zarkavelis G, Papadimitriou K, Petricevic B, Kountourakis P, Kopecky J, Grašič Kuhar C, **Popovic L**, Chilingirova NP, De Mello RA, Dedic N, Katsanos K, Mostert B, Alongi F, de Bari B, Corradini S, Kamplatsas E, Gazouli I, Gkoura S, Amylidi AL, Valachis A Next Generation Sequencing of Circulating Tumor DNA Can Optimize Second Line Treatment in RAS Wild Type Metastatic Colorectal Cancer after Progression on Anti-EGFR Therapy: Time to Rethink Our Approach *Oncol Res Treat*. 2022 Jan 9. doi: 10.1159/000521845. Online ahead of print.

Tan AR, Wright GS, Thummala AR, Danso MA, **Popovic L**, Pluard TJ, Han HS, Vojnović Ž, Vasev N, Ma L, Richards DA, Wilks ST, Milenković D, Xiao J, Sorrentino J, Horton J, O'Shaughnessy J. Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study *Clin Cancer Res*. 2022 Feb 15;28(4):629-636.

Krivokuca A, Mihajlovic M, Susnjar S, Spasojevic IB, Minic I, **Popovic L**, Brankovic-Magic M  
Mutational profile of hereditary breast and ovarian cancer - Establishing genetic testing  
guidelines in a developing country Curr Probl Cancer. 2021 Jul 10:100767.

Matovina Brko G, Popovic M, Jovic M, Radic J, Bodlovic Kladar M, Nikolic I, Vidovic V, Kolarov  
Bjelobrck I, Kukic B, Salma S, Litavski J, Petrovic N, Vranjkovic B, Roganovic T, Ruzic M, Dugandzija  
T, **Popovic L** COVID-19 vaccines and cancer patients: acceptance, attitudes and safety J BUON.  
2021 Sep-Oct;26(5):2183-2190

Davide, Mauri; Kamposioras, Konstantinos; Lampriani, Tsali; Mario, Dambrosio; Bernardino, De  
Bari; Nadia, Hindi; Carl, Salembier; Joanna, Nixon; Dimitrios, Tzachanis; Flippo, Alongi; Hassan,  
Hameed; Antonios, Valachis; Konstantinos, Papadimitriou; Stefanie, Corradini; **Lazar, Popovic**;  
Jindrich, Kopecky; Andres, Rodriguez; Katarina, Antunac; Junlin, Yi; Lovey, Jozsef; Primoz,  
Strojan; Haytham, Saraireh; Ranveig, Røtterud; Marzanna, Chojnacka; Olalla, Santa Cruz;  
Natalia, Chilingirova; Ramon A, De Mello; Giovanna, Araujo Amaral; Farsid, Arbabi; Radu, Vidra;  
Erjeta, Rapushi; D, Takeuchi; Chirstos, Christopoulos; Irina, Ivanova; Igor, Djan; Branka,  
Petricevic; Francesco, Cellini; Iglia, Mihaylova; Natalija, Dedic Plavetic; Cvetka, Grasic Kuhar;  
Elena, Takeuchi; Pantelis, Kountourakis; Panagiotis, Ntellas; Ioanna, Gazouli; Stefania, Gkoura;  
Salih, Yuce; Er, Özlem; Yasmina, Chait; Kumaran, Gireesh; Orges, Spahiu COVID-19 Vaccinations:  
Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient  
Information Rev Recent Clin Trials ; 2021 Oct 28.

**Popovic L**, Matovina-Brko G, Popovic M, Popovic M, Cvetanovic A, Nikolic I, Kukic B, Petrovic D  
Immunotherapy in the treatment of lymphoma World J Stem Cells. 2021 Jun 26;13(6):503-520.

Saif MW, Becerra CR, Fakhri MG, Sun W, **Popovic L**, Krishnamurthi S, George TJ, Rudek MA,  
Shepard DR, Skopek J, Sramek V, Zaric B, Yamamiya I, Benhadji KA, Hamada K, He Y, Rosen L.  
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in  
patients with advanced solid tumors and varying degrees of renal impairment Cancer  
Chemother Pharmacol. 2021 Jun 7.

Tomczak P, **Popovic L**, Barhelemy P, Janicic A, Fernandez ES, Borchiellini D et al. Preliminary  
Analysis of a Phase 2, Multicenter, Randomized, Active-Control Study to Evaluate the Efficacy  
and Safety of Eganalisib (IPI-549) in Combination with Nivolumab compared to Nivolumab  
Monotherapy in Patients with Advanced Urothelial Carcinoma Abstract ASCO GU 2021

Joyce O'Shaughnessy, Gail S Wright, Anu R Thummala, Michael A Danso, **Lazar Popovic**, Timothy  
J Pluard et al. Trilaciclib improves overall survival when given with gemcitabine/ carboplatin in  
patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2  
trial Abstract PD1-06 San Antonio Breast Cancer Symposium 2020

Konstantinos Kamposioras, Davide Mauri, Konstantinos Papadimitriou, Alan Anthoney , Nada  
Hindi , Branka Petricevic, Mario Dambrosio, Antonis Valachis, Pantelis Kountourakis, Jindrich  
Kopecky, Cvetka Grašič Kuhar, **Lazar Popovic**, Nataliya P. Chilingirova, George Zarkavelis,

Ramon Andrade de Mello, Natalija Dedić Plavetić, Christos Christopoulos, Bianca Mostert, John R. Goffin, Dimitrios Tzachanis, Haytham Hamed Saraireh, Fei Ma, Ida Pavese, Maria Tolia  
Synthesis of Recommendations from 25 countries and 31 Oncology societies-The ball of thread to help navigate the COVID-19 labyrinth *Front Oncol.* 2020 Nov 19;10:575148. doi: 10.3389/fonc.2020.575148. eCollection 2020.

Belkacemi Y, Grellier N, Ghith S, Debbi K, Coraggio G, Bounedjar A, Samlali R, Tsoutsou PG, Ozsahin M, Chauvet MP, Turkan S, Boussem H, Kuten A, Tesanovic D, Errihani H, Benna F, Bouzid K, Idbaih A, Mokhtari K, **Popovic L**, Spano JP, Lotz JP, Cherif A, To H, Kovcin V, Arsovski O, Beslija S, Dzodic R, Markovic I, Vasovic S, Stamatovic L, Radosavljevic D, Radulovic S, Vrbanec D, Sahraoui S, Vasev N, Stojkovski I, Risteski M, Freixa SV, Krengli M, Radosevic N, Mustacchi G, Filipovic M, Kerrou K, Taghian AG, Todorovic V, Geara F, Gligorov J. A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries *Eur J Cancer* 2020 Aug;135:130-146.

Mauri D, Kamposioras K, Tolia M, Alongi F, Tzachanis D...Popovic L Summary of International Recommendations in 23 Languages for Patients With Cancer During the COVID-19 Pandemic International Oncology Panel and European Cancer Patient Coalition Collaborators *Lancet Oncol.* 2020 Jun;21(6):759-760.

Mauri D, Tzachanis D, Valachis A et al....Popovic L. on behalf of International Oncology Panel, FAVO and ECPC Behind the numbers and the panic of a viral pandemic: fixed restrictive oncology guidance may jeopardize patients' survival *JBUON* 2020; 25(3): 1277-1280

Tan A, Wright G, Thummala A, Danso M, Popovic L, Pluard T et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial *Lancet Oncol* 2019 Nov; 20(11):1587-1601.

O'Shaughnessy, Wright G, Thummala A, Danso M, Popovic L, Pluard T et al. Trilaciclib improves overall survival when given with Gemcitabine/Carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial *Ann Oncol* 2019: 30 ESMO 2019

Vladimir Todorovic, Matti Aapro, Nicholas Pavlidis, Oliver Arsovski, Yazid Belkacemi, Nada Babovic, François Clément Bidard, Mouna Bourhfour, Semir Beslija, Hamouda Boussem, Bojana Cetnikovic, Timur Cerić, Nada Cicmil, Nebojsa Crnogorac, Enkelejda Cuedari, Michele De Laurentis, Tomislav Dragovich, Ivana Durutovic, Zoran Dzamic, Radan Dzodic, Zivka Eri, Fady Geara, Ahmed Khalil, Khaldoun Kerrou, Slavica Knezevic Usaj, Vladimir Kovcin, Dhurata Koroveshi, Anila Kristo Pema, Abraham Kuten, Jadranka Lakicevic, Nevenka Lukovac, Ivan Markovic, Milan Markovic, Nenad Mijalkovic, Daniela Miladinova, Nikola Milasevic, Giorgio Mustachi, Dragana Ognjenovic, Aleksandra Pantelic, **Lazar Popovic**, Davorin Radosavljevic, Nina Radosevic, Sinisa Radulovic, Milan Ristevski, Ivana Rosic, Nevena Secen, Milan Sorat, Liljana Stamatovic, Petar Stefanovski, Igor Stojkovski, Dusanka Tesanovic, Zorica Tomasevic, Zoran

Tomasevic, Pauletta Tsoutsou, Sedat Turkan, Nino Vasev, Suzana Vasovic, Ferenc Vicko, Damir Vrbanec, Filip Vukmirovic, Eduard Vrdoljak, Bojan Zaric, Jean Jacques Zambrovski, Franco Cavalli, Joseph Gligorov AROME-ESO Oncology Consensus Conference: Access to Cancer Care Innovations in Countries With Limited Resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan) J BUON 2019; 24 (5): 2180-97

Cvetanovic A, Pejic I, Zivkovic N, Krtinic D, Kostic M, Popovic L Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer? J BUON. 2019 Mar-Apr;24(2):516-521.

Popovic M, Matovina-Brko G, Petrovic D, Vranjkovic B, Boskovic-Milosevic B, Popovic L. Prognostic value of age-adjusted international prognostic index in patients with relapsed or refractory diffuse large b-cell lymphoma-single centre experience. 2<sup>nd</sup> Regional congress of medical oncology, Belgrade , Serbia , May 16-18<sup>th</sup> 2019. Archive of Oncol 2019;25(suppl 1) p 3.

Matovina-Brko G, Popovic M, Trifunovic J, Pesic J, Popovic L. First line treatment of HR+/HER- metastatic breast cancer. 2<sup>nd</sup> Regional congress of medical oncology, Belgrade , Serbia , May 16-18<sup>th</sup> 2019. Archive of Oncol 2019;25(suppl 1) p 35.

Popović M, Matovina-Brko G, Petrović D, Vranjković B, Radić J , Popović L. Prognostic value of age-adjusted international prognostic index in patients with relapsed or refractory diffuse large B-cell lymphoma- a single centre experience. Med Pregl 2019;LXXII (1-2): 25-29.

J O'Shaughnessy, GS Wright, AR Thummala, MA Danso, L Popovic, TJ Pluard et al. Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results Cancer Res 2019; 79 (4, Supplement)

S. Susnjar, L. Popovic, A. Cvetanovic, N. Stanic, J. Citic, I. Kolarov-Bjelobrk, M. Popovic, N. Nedovic, A. Stojanovic, G. Matovina-Brko, K. Serovic, N. Milosavljevic, Z. Murtezani, I. Kezic, D. Gavrilovic, S. Radulovic Real world data: Trastuzumab w/o concurrent endocrine therapy in luminal HER2-positive metastatic breast cancer resulted in decreased overall survival Eur J Cancer Supp 2018 (ECCO 2018 Poster)

Popovic L, Tomasevic Z, Stamatovic L, Markovic I, Matovina-Brko G, Buta M, Golubovic A, Selakovic V, Trifunovic J, Mutrezani Z, Ivanovic N, Nedovic J, Ninkovic S, Filipovic S, Cvetanovic A, Djordjevic N, Karanikolic A, Ivkovic-Kapic T, Vicko F. Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE. J BUON. 2018 Mar-Apr;23(2):522-532.

Popovic M, Matovina-Brko G, Popovic L, Vranjkovic B, Novel target and immunotherapy Options in the Treatment of NHL, 9<sup>th</sup> French Serbian Oncology Congress, Novi Sad. 16-17 march 2018, p 2-3.

Popovic L, Popovic M, Vranjkovic B, Matovina-Brko B. Renal Cell Carcinoma Treatment in 2018, 9<sup>th</sup> French Serbian Oncology Congress, Novi Sad. 16-17 march 2018, p 7.

Todorovic V, Aapro M, Pavlidis N, Arsovski O, Belkacemi Y, Babovic N, Bidard FC, Bourhahfour M, Beslija S, Boussem H, Cetnikovic B, Ceric T, Cicmil N, Crnogorac N, Cuedari E, De Laurentis M, Dragovich T, Durutovic I, Dzamic Z, Dzodic R, Eri Z, Geara F, Khalil A, Kerrou K, Knezevic Usaj S, Kovcin V, Korovesi D, Kristo Pema A, Kuten A, Lakicevic J, Lukovac N, Markovic I, Markovic M, Mijalkovic N, Miladinova D, Milasevic N, Mustachi G, Ognjenovic D, Pantelic A, Popovic L, Radosavljevic D, Radošević N, Radulovic S, Risteovski M, Rosic I, Secen N, Sorat M, Stamatovic L, Stefanovski P, Stojkovski I, Tesanovic D, Tomasevic Z, Tomasevic Z, Tsoutsou P, Turkan S, Vasev N, Vasovic S, Vicko F, Vrbanc D, Vukmirovic F, Vrdoljak E, Zaric B, Zambrovski JJ, Cavalli F, Gligorov J. AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan) J BUON. 2019 Sep-Oct;24(5):2180-2197.

Cvetanovic A, Filipovic S, Zivkovic N, Popovic L, Kostic M, Djordjevic M, Karanikolic A, Krtinic D. Ten years of using adjuvant trastuzumab in breast cancer in Serbia - Single institution experience. J BUON. 2018 Mar-Apr;23(2):353-360.

Popovic LS, Matovina-Brko G, Popovic M Checkpoint inhibitors in the treatment of urological malignancies ESMO Open. 2017 Jun 23;2(2):e000165.

Popovic S, Jovanovic D, Mihaljevic B, Andjelkovic N, Marjanovic G, Marisavljevic D, Vlaisavljevic N, Popovic L, Salma S, Agic D, Milosevic R, Smiljanic M, Sretenović S, Djurdjević P, Markovic O, Hajder J, Govedarovic N Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group J BUON. 2017 Mar-Apr;22(2):487-494.

Popovic L, Popovic M Editorial Comment to Clinical Analysis Of Severe Psychiatric Disorders In Patients With Testicular Cancer: A Single-Center Experience Int J Urol 2016

Popovic Dj, Popovic L Obesity and breast cancer - association even more relevant in males? Eur J Intern Med 2016 Apr;29:e11-2.

Popovic L, Matovina-Brko G, Popovic M, Petrovic D, Cvetanovic A, Vukojevic J, Jovanovic D High dose chemotherapy with stem cell support in the treatment of testicular cancer World J Stem Cells 2015; 7(11): 1222-32

Cvetanovic A, Popovic L, Filipovic S, Trifunovic J, Zivkovic N, Matovina-Brko G, Kostic M; Vicko F, Kocic B, Kolarov-Bjelobrck I Young Age and Pathological Features Predict Breast Cancer Outcome-report from a Dual Institution Experience in Serbia J BUON 2015; 20(6): 1407-13

Matovina-Brko G, Nikolin B, Popovic L, Nikin Z, Popovic-Petrovic S, Jovanovic D Paratesticular rhabdomyosarcoma of a young adult Contemp Oncol (Pozn). 2015;19(3):252-6.

Jovanovic D, Petrovic D, Popovic L Target therapy for patients with Non-Hodgkin Lymphomas 3rd Congress of Hematologist Serbia 2015 PP24: 70-71

O. Markovic, L. Popović, D. Marisavljevic, J. Hajder R., Živković, N. Stanisavljevic, D. Jovanovic, B. Filipovic, D. Stanisavljevic, G. Matovina-Brko, T. Matkovic, M. Todorović, D. Petrovic, B. Mihaljevic Prognostic Impact Analysis of absolute lymphocyte count (ALC) and absolute monocyte count (AMC) in patients with Diffuse Large B-Cell Lymphoma 3rd Congress of Hematologist Serbia 2015 OP23: 122

S. Popovic, B. Mihaljevic, N. Vlaisavljevic, L. Popovic, S. Salma, D. Agic, R. Milosevic, M. Smiljanic, S. Sretenovic, P. Djurdjevic, O. Markovic, J. Hajder, N. Govedarevic, D. Zivic, I. Savic, D. Jovanovic, N. Andjelkovic, T. Vukicevic, D. Marisavljevic Rituximab in the treatment of stage III and IV Follicular Lymphoma: Serbian Lymphoma Study Group Reflekt 1 results 3rd Congress of Hematologist Serbia 2015 OP25: 123

Popovic L, Matovina-Brko G. Anti-PD1/PD-L1 checkpoint inhibitors: a new frontier in cancer immunotherapy The second congress of the Serbian association for cancer research Proceedings book 2015 OP04: 14-17

Popovic L. Breast Cancer in very young woman X UMOS Conference Proceedings Book 2015

Popovic L. Target therapy in the treatment of Hodgkin Lymphoma VI NSOC Proceedings Book 2015

Popovic L, Jovanovic D, Knezevic-Usaj S, Nikin Z, Popovic Dj, Matovina-Brko G, Popovic M, Petrovic D The Expression of Molecular Markers As a Prognostic Factor of Diffuse Large B-Cell Lymphoma Treatment in Rituximab Era 1st ESH International Conference on New Concepts in B Cell Malignancies: From Molecular Pathogenesis to Personalized Treatment Abstr 2292 2014.

Popovic L., Jovanovic D., Petrovic D., Nikin Z., Matovina-Brko G., Trifunovic J., Kolarov-Bjelobrck I. Concurrent Chronic Lymphocytic Leukemia And Merkel Cell Carcinoma In Primary Skin Tumor And Metastatic Lymph Node Indian J Hematol Blood Transfus 2014 Sep;30(Suppl 1):422-4.

Popovic L, Trifunovic J, Pesic J, Matovina-Brko G, Kolarov-Bjelobrck I, Memisevic N, Jovanovic D Male Breast Cancer In The Era Of Modern Therapies: Serbian Single Centre Experience Report Breast J 2014 Apr 8. May;20(3):329-30

O. Markovic, L. Popović, D. Marisavljevic, D. Jovanovic, B. Filipovic, D. Stanisavljevic, G. Matovina-Brko, J. Hajder, T. Matkovic, R. Živković, N. Stanisavljevic, M. Todorović, D. Petrovic, B. Mihaljevic Comparison of prognostic impact of absolute lymphocyte count (ALC), absolute monocyte count (AMC), ALC/AMC prognostic score and ALC/AMC ratio in patients with diffuse large B cell lymphoma Eur J Intern Med 2014 Mar;25(3):296-302.

L. Popovic, O. Markovic, D. Jovanovic, D. Marisavljevic, D. Petrovic, B. Mihaljevic, Z. Nikin, T. Matkovic, G. Matovina-Brko, R. Zivkovic Differences in baseline characteristics and survival rates between GCB and non-GCB diffuse large B-cell lymphoma treated with rituximab based immunochemotherapy EJC Suppl 2013 ECCO-ESMO abstract 3629

L. Popovic, O. Markovic, D. Jovanovic, D. Marisavljevic, D. Petrovic, B. Mihaljevic, M. Popovic, T. Matkovic, G. Matovina-Brko, R. Zivkovic CD5-positive versus CD5-negative diffuse large B-cell lymphoma treated with immunochemotherapy: Is there a difference? EJC Suppl 2013 ECCO-ESMO abstract 3630

L. Popovic, Z. Nikin, D. Jovanovic, S. Knezevic-Usaj, M. Popovic, G. Matovina-Brko BAFF, TACI and BCMA receptors expression and their impact on survival of patients with diffuse large b-cell lymphoma EJC Suppl 2013 ECCO-ESMO abstract 3633

Matovina-Brko G., Ruzic M., Fabri M., Popovic L., Kolarov-Bjelobrck I., Trifunovic J., Petkovic D. Treatment of acute hepatitis C in breast cancer patient J chemother 2014 Jun;26(3):180-3

Matovina-Brko G, Nikolin B, Popovic L, Nikin Z, Jovanovic D, Popovic-Petrovic S. Paratesticular rhabdomyosarcoma of a young adult: a case report with review of the literature. Contemporary Oncology 2013 (ahead of print)

Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Mihaljevic B, Stanisavljevic D, Hajder J, Zivkovic R, Petrovic D, Stanisavljevic N, Matovina-Brko G, Todorovic M, Bila J Prognostic Significance Of Low Lymphocytes Count In The Patients With Diffuse Large B Cell Lymphoma (DLBCL) Haematologica 2013 (EHA Abstract)

B. Mihaljevic, D. Jovanovic, N. Andjelkovic, S. Popovic, T. Vukicevic, B. Andjelic, L. Popovic, M. Todorovic, N. Vlaisavljevic, A. Sretenovic, P. Djurdjevic, S. Sretenovic, S. Jankovic, O. Markovic, G. Marjanovic, S. Vrbic, J. Hajder, D. Zivic. Maximizing therapeutic benefit of rituximab for Relapsed/resistant follicular lymphoma: 2 years maintenance therapy results Hematol Oncol 2013: 31 (suppl. 1): 221

Lučić S, Peter A, Jovanović D, Popović L, Lučić A M, Kozarski D, Spirovski M Role Of 18f-Fdg Pet/Ct In Patients With Follicular Lymphoma 2<sup>nd</sup> Balkan Congress of Nuclear Medicine, 2013.

Popovic L, Popovic M, Jelic M Resistance to rituximab treatment: mechanisms and therapeutic interventions. Med Danas 2013 (Ahead of print) (serbian)

Popovic L., Jovanovic D., Popovic Dj. CD30-the head of the TNF family...or the successful story of brentuximab-vedotin Arch Oncol 2013; 21 (1): 17-19

Jelic M, Jovanovic D, Popovic L, Striber-Devaja D Monoclonal antibodies at the Oncology Institute of Vojvodina-5 year expenditure Arch Oncol 2012; 20(3-4): 53-6

Popovic Dj, Popovic L, Stokic E, Tomic-Naglic D, Mitrovic M, Kovačev-Zavisic B Influence of metformin therapy on breast cancer incidence and prognosis. Arch Oncol 2012; 20(3-4): 62-9

L. Popovic, D. Jovanovic, D. Donat, D. Petrovic, T. Roganovic, J.-P. Lotz High dose chemotherapy with autologous stem cell transplantation for the patients with germ-cell cancer J BUON 2013; 18(1): 289-295

Lucic S, Peter A, Jovanovic D, Popovic L, Petrovic D, Lucic M 18F-FDG PET/CT diagnostic value in the temporal follow-up of lymphoma patients. Eur J Nucl Med Mol Imaging 2012; 39: S584

Petrovic D., Jovanovic D., Popovic L. Risk models for predicting chemotherapy-induced neutropenia in patients with solid tumors and malignant lymphoma Haematologica 2012 (EHA 2012; abstr 1784)

B Mihaljevic ,D Antic ,B Andjelic ,L Popovic ,D Agic ,V Nikolic ,S Sretenovic ,V Vukovic New prognostic model in follicular non-Hodgkin lymphoma treated with rituximab chop: association of comorbidities with overall survival Haematologica 2012 (EHA 2012 abstr 1698)

B Andjelic ,D Antic ,V Nikolic ,L Popovic ,V Vukovic ,B Mihaljevic The impact of comorbidity burden on the overall survival in patients with diffuse large B-cell lymphoma Haematologica 2012 (EHA 2012 abstr 1701)

Petrovic-Popovic S, Tomic S, Nedeljkovic M, Popovic L, Matovina G Early rehabilitation in patients with breast carcinoma Vojnosanit Pregl. 2013 Apr;70(4):407-10

Popovic-Petrovic S, Nedeljkovic M, Popovic L, Petrovic V Secondary Lymphedema of the arm in breast carcinoma at the Oncology institute of Vojvodina: 2001 – 2006 Healthmed 2011; 5(6): 1719-25

Popovic L. , Jovanovic D., Petrovic D., Sundji A., Petrovic N., Roganovic T., Kukic B. Prognostic factors in the treatment of primary extranodal diffuse large B-cell lymphoma with rituximab-based immunochemotherapy Haematologica 2011; 96 (Supp 2):560

B. Mihaljevic, D. Antic, B. Andjelic, M. Todorovic, T. Vukicevic, V. Nikolic, I. Pejic, I. Petkovic, S. Popovic, L. Popovic, N. Andjelkovic, S. Sretenovic, M. Smiljenic, O. Markovic, J. Knezevic Prognostic significance of the Ki-67 index in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP-experience of Serbian Lymphoma Study group Haematologica 2011; 96 (Supp 2): 575-6

B. Mihaljevic, D. Antic, B. Andjelic, T. Vukicevic, V. Nikolic, I. Pejic, I. Petkovic, S. Popovic, L. Popovic, N. Andjelkovic, S. Sretenovic, D. Lekovic, M. Smiljanic, O. Markovic, V. Knezevic, V. Kecman Characteristics of 917 Non-Hodgkin's lymphoma patients in Serbia according to the WHO classification of lymphoid neoplasms-LIRA national register-basd study Ann Oncol 2011; 22 (Supp 4): iv204

B. Mihaljevic, B. Andjelic, D. Antic, M. Todorovic, T. Vukicevic, V. Nikolic, I. Pejic, I. Petkovic, S. Popovic, I Savic., L. Popovic, N. Andjelkovic, S. Sretenovic, J. Knezevic, V. Kecman Diffuse large B-cell lymphoma: germinal center vs non germinal center-treatment response on immunochemotherapy. Serbian Lymphoma Study group Ann Oncol 2011; 22 (Supp 4):iv224-5

Jovanovic D., Popovic L. et al Role of PET/CT in diagnosis and treatment of Lymphoma Haematology Congress of Bosnia and Herzegovina, Sarajevo, May 2011.

Jovanovic Da, Petrovic D., Popovic L., Bjelobrk-Kolarov I., Jovanovic Du. Thromboprophylaxis in hospitalized cancer patients Hematol Rep 2011; 3(Supp 1): 19

Stankov K., Bogdanovic G., Kojic V, Stankov S., Jojic N., Popovic L., Popovic S. Expression analysis of genes involved in epigenetic regulation and apoptosis in human malignant cell lines treated by 5-Azacidine J BUON 2011;16 (1):116-122

L. Popovic, D. Jovanovic, D. Donat, D. Petrovic, T. Roganovic, J.-P. Lotz High-dose chemotherapy with autologous stem cell support for the heavily pretreated patients with germ cell tumours: a Serbian single-centre first-experience report Bone Marrow Transpl 2011; 46(Supp 1): 385

L. Popovic, D. Jovanovic, D. Petrovic, A. Sundji, N. Petrovic, T. Roganovic, B. Kukic Treatment of Primary Extranodal Diffuse Large B-cell Lymphoma with Immunochemotherapy-Our Experience 2<sup>nd</sup> Serbian Haematology Congress/6<sup>th</sup> Balkan Day of Haematology Abstract Book Nov 2011:172.

L. Popovic, D. Jovanovic, D. Petrovic, N. Petrovic, A. Sundji, T. Roganovic, G. Matovina-Brko Significance of Standard Prognostic Scores (IPI and R-IPI) in Prognosis of Diffuse Large B-cell Lymphoma Patients treated with Immunochemotherapy 2<sup>nd</sup> Serbian Haematology Congress/6<sup>th</sup> Balkan Day of Haematology Abstract Book Nov 2011:173.

B. Mihaljevic, D. Jovanovic, N. Andjelkovic, S. Popovic, T. Vukicevic, B. Andjelic, L. Popovic, M. Todorovic, N. Vlaisavljevic, A. Sretenovic, P. Djurdjevic, S. Sretenovic, S. Jankovic, O. Markovic, G. Marjanovic, S. Vrbic, J. Hajder, D. Zivic Rituximab in combination with Chemotherapy in Patients with Relapsed/Refractory Follicular NHL-Serbian Lymphoma Study Group Experience. 2<sup>nd</sup> Serbian Haematology Congress/6<sup>th</sup> Balkan Day of Haematology Abstract Book Nov 2011:166.

D. Agic, I. Savic, S. Popovic, I. Percic, V. Kvirgic, B. Sekulic, B. Andjelic, D. Antic, L. Popovic, D. Jovanovic, T. Vukicevic, N. Andjelkovic, S. Vrbic, V. Nikolic, S. Sretenovic, B. Mihaljevic Spread of Diffuse Large B-cell Lymphoma in Serbian Patients 2<sup>nd</sup> Serbian Haematology Congress/6<sup>th</sup> Balkan Day of Haematology Abstract Book Nov 2011:20-22

V. Nikolic, D. Antic, B. Andjelic, M. Todorovic, T. Vukicevic, I. Pejic, I. Petkovic, S. Popovic, L. Popovic, N. Andjelkovic, S. Sretenovic, O. Markovic, J. Knezevic, B. Mihaljevic Prognostic significance of Ki-67 index in Patients with Diffuse Large B-cell Lymphoma treated with Rituximab plus CHOP-Serbian Lymphoma Study Group Experience 2<sup>nd</sup> Serbian Haematology Congress/6<sup>th</sup> Balkan Day of Haematology Abstract Book Nov 2011:23-25

S. Sretenovic, N. Andjelkovic, D. Antic, B. Andjelic, T. Vukicevic, V. Nikolic, S. Popovic, L. Popovic, O. Markovic, J. Knezevic, B. Mihaljevic Prospective non-selective Study of patients with

Lymphoproliferative Neoplasms in Serbia-LIRA National Register 2<sup>nd</sup> Serbian Hematology Congress/6<sup>th</sup> Balkan Day of Haematology Abstract Book Nov 2011:26-29.

B. Andjelic, D. Antic, V. Nikolic, L. Popovic, V. Vukovic, B. Mihaljevic Prognostic Significance of Comorbidity Indices in Diffuse Large B-Cell Lymphoma 2<sup>nd</sup> Serbian Hematology Congress/6<sup>th</sup> Balkan Day of Haematology Abstract Book Nov 2011:34-36. B. Mihaljevic, D. Antic, B. Andjelic, D. Lekovic, D. Jovanovic, L. Popovic, T. Vukicevic, I. Pejic, N. Andjelkovic, P. Djurdjevic, O. Markovic High ki-67 protein expression as prognostic factor in diffuse large B-cell lymphoma – experience of Serbian Lymphoma study Group Abstract 416; International Society of Haematology Congress, Jerusalem, Israel 2010.

Popovic L, Jovanovic D., Matovina-Brko G., Petrovic D., Nikin Z, Roganovic T. Primary diffuse large B-cell lymphoma of the breast Arch Oncol 2009; 17 (3-4): 80-2

Grgic Z, Oros A, Rasic D, Popovic L, Popovic M Ocular malignant melanoma in pregnancy: is a happy ending possible? Arch Oncol 2009; 17 (3-4): 83-5

Popovic L, Jovanovic D, Petrovic D, Matovina G, Roganovic T. ALK-negative large cells lymphoma in skeletal muscle-case report. Medicina Danas 2009; 8(7-9): 249-54. (serbian)

Stankov K, Tauszig-Delamasure S, Bogdanovic G, Popovic L, Stankov S, Sylvius N, Popovic S, Mehlen P. Expression of the genes involved in apoptosis, proliferation and endoplasmic reticulum stress in ionomycin/PMA treated Jurkat cells EJC Supplements (2008), 6(12): 89-90.

Stankov, K; Bogdanovic, G; Popovic L; Popovic, S; Tauszig-Delamasure, S; Mehlen, P; Sylvius, N Expression of c-kit/SCF tyrosine kinase signaling pathway and apoptotic genes in ionomycin/PMA treated Jurkat cells EJC Supplements (2008), 6(9): 147-147

Andrijevic LJ, Aleksic L, Baltic M, Popovic L, Jovanovic D, Petrovic D, Matovina G. Enumeration of haematopoietic CD34+ stem cells by flowcytometry. Balkan flow users meeting Rovinj Croatia 2008.

Popovic L. Rituximab maintenance therapy in follicular lymphoma Arch Oncol 2008;16(1-2): 23. 0

Popovic L. Anti-CD20 MAB(s)..., but not...THERA. Arch Oncol 2008; 16(1-2):23-24.

Popovic L., Jovanovic D., Petrovic D., Matovina G., Roganovic T. „Rituximab in combination with chemotherapy in treatment of diffuse large B-cell lymphoma: our experience“ Abstr.33 Bilt. Hematol 2007; 35(3): 86-100 (serbian)

Popovic L., Jovanovic D., Petrovic D., Matovina G., Roganovic T. „Breast involving lymphoma: report of four cases“ Abstr. 35 Bilt. Hematol 2007; 35(3): 86-100 (serbian)

Popovic L., Jovanovic D., Petrovic D., Matovina G., Roganovic T. „ALK-negative anaplastic large T-cell lymphoma in a muscle: case report and review of literature“ Abstr. 44 Bilt. Hematol 2007; 35(3): 86-100 (serbian)

61. Matovina G., Jovanovic D., Fabri M., Petrovic D., Popovic L., Roganovic T. „Heapatitis B viral infection reactivation during induction lymphoma therapy: report of two cases“ Abstrakt br. 54 Bilt. Hematol 2007; 35(3): 86-100 (serbian)

Tešanovic S. Popovic L.: « Efficacy of lower dose capacitabine in metastatic breast cancer» Sr. Kamenica 2006. (serbian)

Popovic L. «Quality of life in different insuline therapy regimen (CIT, MSII)» Limsc Leiden Holland 2005.